ABNOM
☆ Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
References
Ny laser Q-switched Nd:YAG dia fantatra fa mahomby amin'ny fitsaboana ny nevus an'ny Ota sy ny toe-javatra mitovy amin'izany. Nanao fanadihadiana izahay mba hijerena ny fomba fiasan'ny laser high-fluence 1064 nm Q-switched Nd:YAG amin'ny faritra Mongoliana amin'ny faritra tsy mahazatra, nefa tsy hanamaivana ny hoditra. Nandinika marary 61 izahay miaraka amin'ireo toerana ireo, ka 70 ny fitambarany. Ny antsasaky ny ratra dia notsaboina tamin'ny laser, fa ny hafa kosa tsy voatsabo ho fampitahana. Nanombantombana ny valiny tamin'ny fampiasana mizana sy fitaovana antsoina hoe Mexameter® handrefesana ny haavon'ny melanine izahay. Ny marary dia narahina nandritra ny 14 volana teo ho eo tao amin'ny vondrona fitsaboana ary 18 volana tao amin'ny vondrona mpanara-maso. Tamin'ny fiafaran'ny fianarana dia nahita fahasamihafana lehibe izahay teo amin'ny salan'isa sy ny haavon'ny melanine eo amin'ireo vondrona voatsabo sy tsy voatsabo, miaraka amin'ny vondrona voatsabo tamin'ny laser mampiseho vokatra tsara kokoa. Ny laser high-fluence Q-switched Nd:YAG , tsy miteraka fanamaivanana ny hoditra, dia hita fa mahomby sy azo antoka amin'ny fitsaboana ireo tasy Mongoliana tsy mahazatra ireo.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Nandinika ny fahombiazany sy ny fiarovana amin'ny fampiasana fitsaboana laser manokana ho an'ny ABNOM izahay, ary nijery izay mety hisy fiantraikany amin'ny fiasan'izy io. Nijery marary 110 izahay izay nanana ABNOM ary nahazo fitsaboana laser teo anelanelan'ny roa sy sivy. Hitanay fa niasa tsara kokoa ny fitsaboana rehefa ela no nanaovana azy, fa tsy toy ny tamin'ny marary efa zokiolona. Izy io koa dia niasa tsara kokoa tamin'ny marary manana hoditra maivana (karazana III) sy faritra kely voakasika (latsaky ny 10 cm2) . Ny fananana melasma miaraka amin'ny ABNOM dia nahatonga ny fitsaboana tsy mahomby. Toa tsy nisy fiovana ny loko na ny isan'ny faritra voakasika. Manodidina ny 10% amin'ny marary no nahazo toerana maizina taorian'ny fitsaboana. Ny fitsaboana maromaro tany am-boalohany dia nanome vokatra tsara. Ireo marary efa zokiolona manana hoditra matroka sy miloko maizina kokoa dia mety ho voan'ny pentina kokoa aorian'ny fitsaboana. Ho an'ny marary ABNOM sy melasma, tsara kokoa ny mampiasa laser ambany angovo mba tsy hiharatsy ny melasma.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Fitsaboana
Tsy dia manampy ny Whitening agents. Tsy toy ny melasma, ny ABNOM dia azo hatsaraina amin'ny fitsaboana laser ary avela esorina tsy misy fiverenana. Ny fitsaboana laser dia azo atao in-10 na in-20 amin'ny fitsaboana ny ABNOM.
#QS1064 laser